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Nicotinamide adenine dinucleotide (NAD+) is an essential co-enzyme that can be released in the
extracellular milieu. Here, it may elicit signals through binding purinergic receptors. Alternatively,
NAD+ may be dismantled to adenosine, up-taken by cells and transformed to reconstitute the intra-
cellular nucleotide pool. An articulated ecto-enzyme network is responsible for the nucleotide–
nucleoside conversion. CD38 is the main mammalian enzyme that hydrolyzes NAD+, generating
Ca2+-active metabolites. Evidence suggests that this extracellular network may be altered or used
by tumor cells to (i) nestle in protected areas, and (ii) evade the immune response. We have
exploited chronic lymphocytic leukemia as a model to test the role of the ecto-enzyme network,
starting by analyzing the individual elements that make up the whole picture.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Tumor/host interactions are regulated at multiple levels. These
recapitulate essential mechanisms, selected during phylogeny and
ontogeny, that constitute a system of response to the environment.
Tumor transformation causes neoplastic cells to acquire some of
these mechanisms, enabling them to evade the effects of the host
immune system [1,2]. From a phylogenetic point of view, the most
rudimentary mechanismsmediating interactions with the environ-
ment are believed to hinge upon the effects of monomorphic solu-
ble factors, which regulate crucial signals for the life and death of
cells. Among these factors are extracellular nucleotides, the en-
zymes that metabolize them and their receptors [3]. The ﬁnal ef-
fects stemming from the complex balance between them are
multiple, ranging from activation of cellular motility and differen-
tiation to the control of lymphocyte populations with regulatory
power. For these reasons, pharmacological manipulation of the
system is expected to have important therapeutic implications [4].chemical Societies. Published by E
ool of Medicine and Human
rin, Italy.
.2. Extracellular NAD+ balance
Among extracellular nucleotides, nicotinamide adenine dinu-
cleotide (NAD+) is a co-enzyme found in all living cells, where it
acts as an essential co-enzyme in redox reactions by transferring
electrons. It is also involved in other cellular processes, as a sub-
strate of enzymes post-translationally modify proteins, by adding
or removing chemical groups. The concentration of NAD+ in human
plasma ranges between 10 and 50 nM [5], depending on the bal-
ance between the opposing processes of dinucleotide release from
cells and its enzymatic degradation [5]. However, NAD+ levels in
speciﬁc tissue districts may be signiﬁcantly higher than those in
plasma, especially during inﬂammation [6–8]. Outside cells,
NAD+ may work as a cytokine, eliciting rapid functional responses
through binding to speciﬁc purinergic type 2 receptors. The signal-
ing cascade and the outcome differ according to cell type and envi-
ronment. A positive signal is observed in human granulocytes,
where NAD+ activates the purinergic receptor P2Y11 that results
in cell activation [9]. Negative effects are detected in gastrointesti-
nal myocytes, where NAD+ also activates the purinergic receptor
P2Y11, in this instance behaving as an inhibitory neurotransmitter
[10]. NAD+ exploits different receptors in human monocytes,
namely P2X1, P2X4, and P2X7, which trigger Ca2+ inﬂux [11]. Other
vital functions are controlled by NAD+ in mesenchymal stem cells,lsevier B.V. All rights reserved.
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and cytokines [12].
Besides binding to purinergic receptors, extracellular NAD+ can
be rapidly downgraded by the concerted action of speciﬁc ectoen-
zymes. CD38 (EC 3.2.2.6), the main mammalian NAD+ase, hydro-
lyzes NAD+, generating adenosine dinucleotide phosphate ribose
(ADPR) and nicotinamide. The latter compound can be transformed
to adenosine monophosphate (AMP) by the ectonucleotide pyro-
phosphatase/phosphodiesterase (ENPP) family of enzymes and
then converted to adenosine via CD73 (EC 3.1.3.5). Adenosine,
the ﬁnal product of the reaction, can in turn bind to unique puri-
nergic type 1 receptors [13] and elicit signals through the elevation
of cAMP levels (Fig. 1). Adenosine can also be internalized and used
intracellularly to reconstitute the nucleotide pool, making the net-
work an efﬁcient scavenging system. However, these NAD+-metab-
olizing enzymes not only provide a recycling apparatus, but also
serve as an integrated regulatory component of a network of sig-
nals mediated by P2 and P1 receptors. On the one hand, they con-
trol the generation of NAD+ intermediates and of adenosine, both
of which can modulate signal transduction, often leading to effects
contrary to those seen with the dinucleotide [14]. On the other
hand, they can also act in competitive terms by limiting NAD+
availability for other cell surface enzymes, namely the ADP ribosyl
transferases (ARTs). ARTs post-transcriptionally modify P2 recep-
tors, ultimately leading to their functional activation [15] (Fig. 1).
A yet unexplored possibility is that the presence of an extracellular
NAD+-metabolizing enzymatic complex might impact on the intra-
cellular NAD+ levels. If so, then one might expect signiﬁcant conse-
quences on the function of sirtuins and PARPs, NAD+-dependent
nuclear enzymes that regulate vital cellular processes.
The rather limited knowledge currently available on the impact
of this extracellular signaling network on cellular homeostasis is
largely derived from simpliﬁed in vitro models and knock-out
mice. Within the immune system, it appears to be a criticalFig. 1. Extracellular NAD+ pathways. Once in the extracellular milieu, NAD+ can function
prototype NAD+ receptor), an event that leads to intracellular signaling. On the other han
involved in scavenging of nucleotides. The end product of the reaction, adenosine, can the
intermediates as well as the ﬁnal product, however, can be used as signaling molecules
ryanodine (RyR) or TRPM2 receptors. Adenosine itself can modify signal transduction
concentrations of substrates and products and on the expression of purinergic receptorselement of the modulation of homing and the complex processes
underlying immunoregulation. The extracellular network control-
ling NAD+ levels may serve as an ampliﬁcation mechanism for che-
motactic signals. Indeed, NAD+ has been shown to act directly
through binding P2Y11 receptors, leading to functional activation
of human granulocytes [9]. Alternatively, NAD+ could also be rap-
idly converted into cyclic ADPR (cADPR) and ADPR by the CD38
ectoenzyme family [16]. These two metabolites are intracellular
Ca2+ mobilizers through binding to ryanodine receptors (cADPR)
[17,18] or TRPM2 channels (ADPR) [19], and provide an essential
second signal for chemotaxis. This was shown in murine models,
where Cd38-deﬁcient neutrophils could not efﬁciently follow a
chemotactic gradient and consequently their accumulation at
infection sites was compromised [20]. For these reasons, CD38 is
considered a critical element in the chemotactic response of hu-
man B lymphocytes [21,22], dendritic cells [23] and lymphokine
activated killer cells [24].
vThe second process in which the balance of extracellular NAD+
plays a crucial role is immunomodulation. The immunomodulatory
functions of NAD+ are mainly linked to the activation of ARTs, cell
surface enzymes that transfer the ADP moiety of NAD+ to speciﬁc
amino acids (e.g., arginine) on target proteins [25]. The P2X7 recep-
tor is a critical target of ARTswhose ADP-ribosylation causes activa-
tion resulting in apoptotic cell death [26,27]. This phenomenon has
been termed NAD+-induced cell death (NICD) [25]. Given that P2X7
expression is limited to naïve/resting T lymphocytes, P2X7-medi-
atedNICD speciﬁcally targets this populationandhasbeenproposed
as a homeostatic mechanism for regulatory T cells (Tregs) [28,29].
3. NAD+ balance in cancer: the chronic lymphocytic leukemia
model
Evidence suggests that these network systems might be altered
during tumor transformation. First, tumor development anddirectly by binding purinergic receptors (the P2Y11 receptor is represented as the
d, NAD+ can also be metabolized by a series of enzymes of the cell surface that are
n be internalized and reconverted to related nucleosides (e.g., ATP or NAD+). All the
. cADPR and ADPR are potent intracellular Ca2+-mobilizing agents through binding
by acting on P1 purinergic receptors. The ﬁnal outcome depends on the relative
and nucleotide-metabolizing ecto-enzymes.
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mechanisms. Theonset of hypoxic andpro-inﬂammatory conditions
is associatedwith cellular stress and damage and hence to increased
extracellular NAD+ levels [30]. Second, the expression of NAD+-
metabolizing enzymes is increased during cellular activation and,
in some instances, of tumor transformation. Themost typical exam-
ple is CD38, which is rapidly up-regulated as a consequence of
inﬂammatory signals and conditions (reviewed in [16]). Further-
more,many hematopoietic tumors, including leukemias andmyelo-
mas, express high levels of surface CD38. Indications of increased
expression during tumor transformation also holds true for CD73,
which is present at high levels in most tumors of epithelial origin
[31], as well as in subsets of hematological malignancies [32].
Although their expression proﬁle is not as well characterized, E-
NPPs appear to be highly expressed in tumors of thebasophil lineage
[33]. And while even less is known about the expression proﬁle of
purinergic receptors in cancer cells, P2X7 does appear elevated in
some tumor models [34].
In light of the above, it seems entirely possible that the interac-
tion between extracellular NAD+, ectoenzymes involved in its
metabolism and purinergic receptors can be altered or exploited
by tumor cells to (i) nestle in protected areas, and (ii) evade the im-
mune response. The disease model we used to test this hypothesis
is chronic lymphocytic leukemia (CLL), which is the most frequent
leukemia in Europe and North America and is characterized by the
expansion of a monoclonal population of mature B cells expressing
CD5 and CD23 [35]. CLL is a highly heterogeneous, incurable dis-
ease that ranges from a stable condition not requiring treatment
to a rapidly progressive disease unresponsive to therapy. These
drastic differences in manifestation raise clinically relevant ques-
tions, boosting interest in the disease [36].
Another reason for our choice of disease model is that CLL cells
may express CD38 [37], alongwith a number of purinergic receptors
(e.g., P2X7 [38]). The presence of CD38 on the cell surface has prog-
nostic relevance, with high levels being associated with an unfavor-
able outcome [39]. Within the same clone, CD38 expression deﬁnes
a subset of cells rich in Ki-67 and in telomerase activity [40] and
characterized by the differential expression of a set of genes in-
volved in chemotaxis and migration [41]. The latter observation is
of particular interest, given that recirculation of CLL cells fromblood
to lymphoid organs is now generally accepted as a key step in tumor
maintenance, progression and resistance to therapy [42,43]. The
molecular mechanisms regulating homing are thus pathogenetical-
ly important and therapeutically relevant in light of recentdata indi-
cating that the proliferative core of the disease resideswithin lymph
nodes (LN) and bone marrow (BM) [44]. Lastly, CLL is frequently
associated with clinically manifest immune defects, pointing to an
underlying immune dysregulation. CLL cells express high levels of
immunomodulatory factors (e.g., TGF-b [45] and IL-10 [46]) that
not only suppress response to antigens, but also the activation,
expansion, and effector functions of T lymphocytes [47]. Further-
more, increased numbers of Tregs have been reported [48,49].
These factors all bring to bear on the choice of CLL as the disease
model for investigating the role of the extracellular NAD+ network
in contributing to leukemia development and progression. Our ap-
proach to this complex topic has been to start analyzing individual
elements making up the whole. Because of its relevance in deter-
mining clinical prognosis, the focus has been on the expression
and function of CD38 in the context of leukemia. Before delving
into the topic, we will give a brief overview of the main structural
and functional characteristics of the molecule.
4. Structure and function of CD38
Human CD38 is a type II surface glycoprotein characterized by a
large extracellular domain, a single transmembrane pass and ashort cytoplasmic tail [50]. Within the human immune system, it
is expressed by immature hematopoietic cells, down-regulated
by mature lymphocytes and re-expressed at high levels by acti-
vated T and B, dendritic and natural killer (NK) cells [16].
CD38 is the main mammalian member of the ADP ribosyl cy-
clase (ADPRC) family of enzymes and seemingly ubiquitous in
eukaryotic cells [51]. This family of enzymes has Aplysia californica
as its founding cloned member. A. californica is present in soluble
form in the ovotestis of the mollusk and its functions are linked
to fertilization [52]. The human version retains high homology
with its Aplysian ancestor, speciﬁcally around the enzymatic site;
however, its functional activities have extensively evolved. The
ADPRC from Aplysia cyclizes NAD+ by linking the N1-position of
the adenine ring to the anomeric carbon of the terminal ribose, dis-
placing the nicotinamide group [53,54]. Instead, human CD38 is
mainly a NAD+ glycohydrolase that leads to the generation of ADPR
and nicotinamide as products, accounting for >90% of all NAD+ase
activities in humans [55]. The cyclase function is present, but it
is approximately 100-fold lower than that of the hydrolase. A fur-
ther limitation in the production of cADPR derives from the efﬁ-
cient conversion of cADPR to ADPR performed by the human
enzyme [56]. CD38 can also use NADP as substrate and generate
NAADP in the presence of nicotinic acid. Thus, ADPR, cADPR and
NAADP may be produced as a result of CD38 enzymatic activities,
while microenvironmental conditions (e.g., Zn2+ ions) may shift the
balance from one to another [57].
The feature shared by these products is that they are all ligands
for receptor/channels operating inside the cell and regulating gra-
dient-mediated inﬂux of Ca2+ ions from different stores [58].
The most radical change in the evolutionary path followed by
CD38 was that of acquiring a membrane anchor. The human pro-
tein is localized in the plasma membrane and, according to some
reports, in the nuclear one as well [59]. Having a membrane anchor
made it possible for CD38 to interact laterally and frontally with
molecules other than the substrate. A common pattern is that
CD38 organizes the formation of supra-molecular complexes that
generally include other receptors, adhesion molecules and struc-
tural proteins [16]. These complexes tend to be present in lipid
rafts, cholesterol-rich areas of the plasma membrane, where signal
transduction can proceed efﬁciently [60,61]. CD38 can also bind to
CD31 expressed by juxtaposed cells: this interaction induces acti-
vation, proliferation and cytokine release in selected lymphocyte
subsets [62]. Much less studied are the interactions on the intracel-
lular side of the membrane; however, it appears that CD38 can
attract transducers and adaptors, in spite of its short and non-
descript tail [63–65].
Following an enzyme-centric view of CD38, all these interac-
tions could be taken as another element in the regulation of enzy-
matic activity that is critical for cell homeostasis. According to this
view, the human enzyme would be limited in action not only by
the availability of the substrate, but also by the opening or closing
of the enzymatic site, governed by interaction with other mole-
cules. Indirect support for this hypothesis comes from the crystal
resolution of CD38, which clearly appears as a dimer coupled to
different ligands [66,67]. Activation of CD38 has been extensively
studied using agonistic (i.e., eliciting activatory signals) monoclo-
nal antibodies (mAbs) [68]. These studies have shown that trans-
mission of signals through CD38 is tightly regulated at distinct
levels. The ﬁrst involves the structural organization of CD38, di-
vided into mono- and multi-meric forms, with separate enzymatic
and receptor functions. The second is based on the dynamic local-
ization of the molecule in lipid microdomains within the plasma
membrane [63,60]. A signiﬁcant fraction of the membrane CD38
pool is constitutively localized in cholesterol-rich regions,
while the remaining fraction of CD38 joins the raft pool upon
engagement with agonistic mAbs and other bona ﬁde ligands
T. Vaisitti et al. / FEBS Letters 585 (2011) 1514–1520 1517[61]. Disruption of the rafts prevents signal transduction through
CD38. The third level of control is determined by lateral associa-
tions on the same cell with other proteins or protein complexes,
which include antigen receptors, adhesion molecules, chemokine
receptors and tetraspanins. Lastly, recent data indicate the pres-
ence of distinct pools of CD38 molecules, not only on the cell sur-
face, but also in internal compartments (endoplasmic reticulum,
endosomes, and nucleus) and in secreted exosomes [69].
Once CD38 is activated, the essential steps of the pathway
invariably involve an increase in intracellular Ca2+ and tyrosine
phosphorylation of sequential signal transducers. There is a long-
standing and still unsolved debate on the role of the enzymatic
activity in the initiation of the signaling cascade. Studies are gener-
ally limited by the unavailability of potent and speciﬁc inhibitors of
CD38; the complexity and variety of the enzymatic products adds a
further complication.5. CD38 is a master regulator of CLL cell homing
The determination of CD38 expression on the surface of CLL
cells has become a widely used tool to help clinicians in making
prognosis at diagnosis. More than 15 independent studies per-
formed in different institutes and using different detection meth-
ods and cut-offs have uniformly concluded that the molecule is
an independent negative prognostic marker [37]. We took these
observations as our starting point, addressing the issue of the role
exerted by this multifunctional enzyme/receptor molecule in CLL
pathogenesis and progression.
The earliest results were obtained by using agonistic mAbs as
tools to manipulate the molecule and study the ensuing intracellu-
lar events. Those experiments allowed to conclude that mAb expo-
sure in the presence of interleukin-2 (IL-2) was followed by a
marked proliferative response and by the acquisition of immuno-
blast-like features by a subset of the clone [70]. The same effects
could be reproduced at least in part by substituting the mAb with
the CD31 ligand, expressed by mouse transfectants [71]. The gene
expression proﬁle induced after CD38/CD31 binding was highly
informative in providing genetic evidence that this cross-talk acti-
vates proliferative pathways as well as a pro-migratory phenotype
[72]. The latter observation was particularly attractive, considering
the current view of the disease as a balance between proliferating
cells in lymphoid organs and apoptosis-resistant ones in the circu-
lation [42,73]. When addressed experimentally, the association be-
tween CD38 expression and chemotaxis turned out to be highly
signiﬁcant [21,22]. This conclusion was reached by several inde-
pendent experimental approaches.
The ﬁrst indication came from the ﬁnding of a clear-cut correla-
tion between the presence of an active CD38 signaling pathway
and increased sensitivity of CLL cells to CXCL12, the main chemo-
kine involved in the recirculation of leukemic cells to and from
lymph nodes. Secondly, the migratory population is the CD38+
one, as indicated by conventional chemotaxis assays, showing a
selective increase in the percentage of these cells in the lower sec-
tion of the Boyden chamber. Moreover, the use of leukemic cells
from patients with a bimodal expression of CD38 indicated that
the negative component of the clone was signiﬁcantly less respon-
sive to the chemokine both in terms of ERK1/2 phosphorylation,
used as a read-out of the activation of the CXCR4 signaling path-
way, and chemotaxis than the intact clone, in spite of comparable
expression levels of CXCR4 [22]. The use of CLL cells with a bimodal
expression of CD38 is a controlled experimental approach because
it offers the possibility to study the functional differences between
the two components of the same clone, hence sharing the genetic
background [41]. A further conﬁrmation of the role played by
CD38 in the regulation of chemotactic response to CXCL12 wasobtained genetically manipulating CD38- CLL cells with a lentiviral
technique [74]. The de novo acquisition of CD38 surface expression
by leukemic cells was followed by a signiﬁcant increase in the
migratory properties [22].
The functional synergism between CD38 and CXCR4 was further
highlighted using a panel of anti-CD38 mAbs. The agonistic mAb
was able to enhance the chemotaxis of CLL cells in response to
CXCL12, while the blocking mAbs signiﬁcantly interfere with the
signaling pathway. These data were conﬁrmed also in an in vivo
model of NOD/SCID mice: pre-treatment of leukemic cells with
blocking anti-CD38mAbs resulted in an impaired homing to spleen
and bone marrow, in a comparable way to that obtained with a
speciﬁc anti-CXCR4 mAb. A possible explanation of the functional
results was the physical proximity of these two molecules on the
cell surface of CLL cells. Confocal microscopy and co-immunopre-
cipitation experiments revealed that CD38 and CXCR4 co-localize,
at least in part, in the same membrane areas [22].
The ability of leukemic cells to recirculate from blood to lym-
phoid organs is not only due to the functional response to chemo-
kines. Leukocyte trafﬁcking is orchestrated and controlled by the
functional cooperation of several molecules, expressed both by
leukemic cells and the vascular endothelium. Several in vitro and
in vivo studies have established that the homing process is regu-
lated by sequential steps mediated by speciﬁc subsets of adhe-
sion/integrin molecules that regulate interactions between
leukocytes and their endothelial ligands. Another relevant family
of molecules involved in this physiological process is the matrix
metalloproteinases (MMPs), enzymes able to digest the extracellu-
lar matrix leading to the extravasation of leukocytes.
Integrins are known to be involved in a bidirectional signaling
mechanism, where the activation of outside–inside pathway that
follows ligation, inﬂuences cellular process through the interac-
tions with cytoskeletal structures and signaling proteins. Several
integrins are implicated in the invasive and migratory functions
of a variety of malignancies. Indeed, they play a signiﬁcant role
in the acquisition of a neoplastic/invasive phenotype mediating
cell proliferation, prevention from apoptosis and operating in asso-
ciation with chemokine receptors. In the CLL context, support to
this hypothesis comes from experimental data showing that
CD31/CD38 signals are part of a molecular circuit involving the
CCL3 and CCL4 chemokines and the integrin CD49d (a4), a further
negative and independent prognostic marker for the disease [75].
The a4 integrin, through the binding to vascular cell adhesion mol-
ecule-1 (VCAM-1) or to the CS-1 fragment of the ﬁbronectin, regu-
lates CLL cell extravasation [76]. Experimental data shows that
CD31/CD38 interactions result in the rapid release of a panel of
chemokines by CLL cells. The ﬁnal effect is the expression of
VCAM-1 by stromal and endothelial cells, with the activation of
pro-survival signals in CLL cells mediated by CD49d/VCAM-1 axis
[75]. The functional link between CD38 and CD49d seems to reside
on their physical proximity on the CLL cell membrane, suggesting
the presence of a large supra-molecular complex that tunes the
adhesion and chemotactic response of CLL cells.
An important step in the homing and cell migration during tu-
mor invasion is structural changes in the extra-cellular matrix. A
relevant role in this remodeling process is played by MMPs and
the activation of several integrins may lead to enhanced expression
or maturation of MMPs, allowing for the local degradation of ECM
components. In the CLL model, MMP-9 is the predominant gelatin-
ase expressed and its intracellular levels correlate with advanced
stage of the disease and poor patient survival [77,78]. Moreover,
recent experimental data support the involvement of MMP-9 in
CLL cell migration and survival, suggesting that the proteolytic
activity may be enhanced by its localization on the CLL cell surface.
CD49d/CD29 integrins and the ‘‘v’’ variant of CD44 (CD44v) were
identiﬁed as docking molecules for MMP-9 [79]. CD44 is involved
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ported to contribute to extravasation by associating with CD49d.
CD44 is the major receptor for hyaluronan (HA), but binds also to
ﬁbronectin, and is important in leukocyte rolling and adhesion to
vessel endothelium [80]. The latter is due to an association be-
tween CD44 and CD49d, where CD49d/CD29 promotes ﬁrms adhe-
sion through the binding to VCAM-1 [81].
The hypothesis of a possible role of CD44v as a regulator of CLL
chemotaxis through the modulation of MMP-9 localization may be
important and must be explored considering also that CD38 might
be involved in the binding of glycosamiglycans, sharing them with
CD44 [82].
These results and considerations suggest the existence of a large
supra-molecular complex on the leukemic cell surface that in-
cludes chemokine receptors, integrins, MMPs and CD38. The latter
molecule should be a bridging element, functionally cooperating
with the other molecules and leading to the higher migratory po-
tential of CD38+ CLL cells.
6. CD38 and homing: how does it work? Speculative hypotheses
While these ﬁndings may provide an initial explanation for the
clinical observation that patients with CD38+ CLL clones experience
a generally more aggressive disease and a worse prognosis, they
also prompt further questions.
The central question that still needs to be resolved from a basic
science point of view is how CD38 expression can facilitate the
homing process. Are the effects obtained through modulation of
extracellular NAD+ levels or through the generation of Ca2+ active
compounds or through structural re-organization of the mem-
brane? Investigators are faced with several vexing issues in design-
ing experiments. First, the known enzymatic inhibitors for CD38
are highly inefﬁcient and generally toxic to cells, making it difﬁcult
to draw ﬁrm conclusions [83]. Second, because the enzymatic
activity is complex and multifunctional, individual contributionsFig. 2. Speculative hypothesis on the mechanisms of action of CD38 in directing CLL cel
leakage or active membrane passage of NAD+ from the inside to the outside, following a c
cADPR and ADPR. These two intermediates trigger Ca2+ inﬂux from the extracellular space
to RyR). The ﬁnal outcome is the relative stabilization and ampliﬁcation of chemokine-in
increase in Ca2+ concentrations might also trigger direct activation of Ca2+-sensitive tyro
This could eventually lead to the polymerization of actin ﬁlaments and to the implementa
some extent, complementary – hypothesis is that the presence of CD38 confers a structu
highly stable supramolecular complexes that include surface molecules as well as intraare hard to identify [56]. Third, the effects of both mAb binding
and CD31 binding on the enzymatic site remain unknown [72].
Indirect evidence from crystallographic studies seems to indicate
that CD31 binding could modify the tri-dimensional structure of
CD38, making the enzymatic site accessible to the substrate [66].
From a purely speculative point of view, chemokine binding
could lead to membrane distortion with possible leakage or active
membrane passage of NAD+ from the inside to the outside, follow-
ing a concentration gradient [22]. The presence of CD38 would
induce NAD+ hydrolysis, generating ADPR and – at lower levels –
cADPR. These two intermediates could be transported inside the
cell by CD38 itself or by active channels, where they could then
trigger Ca2+ inﬂux from the extracellular space (by ADPR binding
to TRPM2) or from the endoplasmic reticulum (by cADPR binding
to RyR) [19]. The ﬁnal outcome would be the relative stabilization
and ampliﬁcation of chemokine-induced signals, leading to en-
hanced activation of cytoplasmic mediators. A localized increase
in Ca2+ concentrations might also trigger direct activation of
Ca2+-sensitive tyrosine kinases [84], and direct nuclear transloca-
tion of Ca2+-sensitive transcription factors [85]. This could eventu-
ally lead to the polymerization of actin ﬁlaments and to the
implementation of a transcriptional program regulating prolifera-
tion. If this is the case, then CD38 could play direct functions and
transmit its own indirect signals, rather than functioning merely
as a molecular ampliﬁer. The alternative – or, to some extent, com-
plementary – hypothesis is that the presence of CD38 confers a
structural advantage to this articulated membrane microdomain,
inducing the formation of highly stable supramolecular complexes
that include surface molecules as well as intracellular signaling
adaptors [23,61,86] (Fig. 2).
7. Conclusions and perspectives
Experience obtained in patients and in vitro after culturing
and manipulating CLL cells has taught us that what is clinicallyl homing. (A) Chemokine binding could lead to membrane distortion with possible
oncentration gradient. The presence of CD38 induces NAD+ hydrolysis and generates
(by ADPR binding to TRPM2) or from the endoplasmic reticulum (by cADPR binding
duced signals, leading to enhanced activation of cytoplasmic mediators. A localized
sine kinases, and direct nuclear translocation of Ca2+-sensitive transcription factors.
tion of a transcriptional program regulating proliferation. (B) The alternative – or, to
ral advantage to this articulated membrane microdomain, inducing the formation of
cellular signaling adaptors.
T. Vaisitti et al. / FEBS Letters 585 (2011) 1514–1520 1519considered to be the most aggressive form of the leukemia is, in
fact, the most fragile. CLL cells bearing markers of aggressive dis-
ease die easily in culture and appear to have major impairments
in vital signaling pathways, such as the one regulated by the anti-
gen. One possible explanation for this apparent contradiction is
that CLL cells from patients with aggressive disease are more
dependent on the external environment and, once plated in an arti-
ﬁcial culture setting, die rapidly in the absence of supporting sig-
nals from other cells. This hypothesis highlights the central role
of the host environment in CLL progression and suggests that tar-
geting the host might be a valuable complementary therapeutic
approach. In this context, elucidation of the distinct microenviron-
mental components of the network of signals sustaining the tumor
takes center stage. Expanding on experience obtained with CD38
ﬁrst as a marker and then as a key element in a pathogenetic net-
work, one might suppose that other enzymes, components of the
chain that dismantles nucleotides, might contribute to modifying
the environment and making it favorable to the neoplastic clone.
If the observations obtained using solid tumor models are con-
ﬁrmed in the context of leukemia, therapeutic strategies targeting
this axis may prove to be effective in ﬁghting the disease.
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